- Home
- AIXI vs NRSN Comparison
AIXI vs NRSN Comparison
Compare AIXI & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIXI
- NRSN
- Stock Information
- Founded
- AIXI 2001
- NRSN 2017
- Country
- AIXI China
- NRSN Israel
- Employees
- AIXI N/A
- NRSN N/A
- Industry
- AIXI Computer Software: Prepackaged Software
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- AIXI Technology
- NRSN Health Care
- Exchange
- AIXI Nasdaq
- NRSN Nasdaq
- Market Cap
- AIXI 31.2M
- NRSN 58.8M
- IPO Year
- AIXI 2023
- NRSN 2021
- Fundamental
- Price
- AIXI $2.82
- NRSN $1.89
- Analyst Decision
- AIXI
- NRSN Buy
- Analyst Count
- AIXI 0
- NRSN 2
- Target Price
- AIXI N/A
- NRSN $14.00
- AVG Volume (30 Days)
- AIXI 107.7K
- NRSN 442.8K
- Earning Date
- AIXI 05-15-2025
- NRSN 07-11-2025
- Dividend Yield
- AIXI N/A
- NRSN N/A
- EPS Growth
- AIXI N/A
- NRSN N/A
- EPS
- AIXI N/A
- NRSN N/A
- Revenue
- AIXI $70,314,315.00
- NRSN N/A
- Revenue This Year
- AIXI $26.84
- NRSN N/A
- Revenue Next Year
- AIXI N/A
- NRSN N/A
- P/E Ratio
- AIXI N/A
- NRSN N/A
- Revenue Growth
- AIXI 18.84
- NRSN N/A
- 52 Week Low
- AIXI $2.06
- NRSN $0.51
- 52 Week High
- AIXI $8.31
- NRSN $2.60
- Technical
- Relative Strength Index (RSI)
- AIXI 52.18
- NRSN 47.36
- Support Level
- AIXI $2.72
- NRSN $1.77
- Resistance Level
- AIXI $3.10
- NRSN $2.35
- Average True Range (ATR)
- AIXI 0.26
- NRSN 0.25
- MACD
- AIXI 0.07
- NRSN -0.08
- Stochastic Oscillator
- AIXI 83.60
- NRSN 12.47
About AIXI XIAO-I Corporation
XIAO-I Corp is an AI industrialization company focusing on the AI Cognitive Intelligence platform. The platform combines six core technologies including Natural Language Processing, Speech Processing, Computer Vision, Machine Learning, Affective Computing, Data Intelligence, and Hyper- automation. Based on the platform, The company developed products and solutions in the fields of Al+ Contact Center, Al+ Finance, Al+ City Public Service, Al+ Architecture, Al+ Metaverse, Al+ Manufacturing, and Al+ Healthcare. It generates revenue from the sale of software products and services, M&S services, and the sale of cloud platform products.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.